The government alleged HDL and Singulex, along with other parties, unlawfully paid physicians handling fees of between $10 and $17 for each patient they referred to the labs for blood tests. The labs also allegedly routinely waived patient co-payments and deductibles.
The physician kickbacks led to patients being referred to the labs for unnecessary tests, which were then billed to federal healthcare programs, according to the DOJ.
Under the settlement agreement, HDL will pay $47 million and Singulex will pay $1.5 million. HDL and Singulex have also agreed to enter into corporate integrity agreements with HHS.
The allegations made against the two companies stem from three lawsuits filed under the qui tam, or whistle-blower, provision of the False Claims Act.
More articles on health law:
Should St. Luke’s antitrust case be reheard? 17 law professors think so
Massachusetts AG backs bill toughening hospital merger oversight
Ariz. law allows patients to order their own lab tests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
